Effect of empagliflozin on the renin-angiotensin system in patients with chronic kidney disease with and without type 2 diabetes.
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Renal failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EMPRA
- 11 Sep 2017 Status changed from not yet recruiting to recruiting.
- 29 Nov 2016 New trial record